Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

Core Viewpoint - Day One Biopharmaceuticals is set to report its financial results and corporate progress for Q4 and full-year 2025 on February 24, 2026, highlighting its commitment to developing targeted therapies for life-threatening diseases, particularly in pediatric cancer [1]. Group 1: Company Overview - Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company focused on addressing the unmet needs in pediatric cancer treatment [3]. - The company aims to redefine cancer drug development and improve outcomes for patients of all ages from the moment of diagnosis [3]. Group 2: Pipeline and Development - Day One's pipeline includes tovorafenib (OJEMDA™), DAY301, and Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate targeting the B7-H4 protein, currently in clinical development for adenoid cystic carcinoma (ACC) [4]. - The recent acquisition of Mersana Therapeutics enhances Day One's capabilities in developing targeted cancer treatments [4]. Group 3: Communication and Accessibility - A live conference call and webcast will be available for stakeholders to access financial results and corporate updates [2]. - An archived version of the webcast will be accessible for 30 days post-event, ensuring continued engagement with investors and the public [2].